BRAINSTORM CELL THERAPEUTICS Business Summary

Brainstorm Cell Therapeutics Inc. (BCLI) is a clinical-stage biotechnology company that currently generates no product revenue, instead funding operations through equity financing, private placements, and research grants. The company’s primary business segment is the development of its proprietary NurOwn® platform, an autologous cell therapy that induces bone marrow-derived mesenchymal stem cells (MSCs) to secrete neurotrophic factors (NTFs) to treat neurodegenerative diseases. Its lead candidate, debamestrocel, is currently in a Phase 3b registrational trial (ENDURANCE) for Amyotrophic Lateral Sclerosis (ALS) following a 2025 FDA clearance under a Special Protocol Assessment. BCLI competes directly with firms such as Amylyx Pharmaceuticals, Cytokinetics, and Denali Therapeutics, positioning itself as a niche leader in autologous "living drug delivery" systems designed to modulate neuroinflammatory processes and promote neuronal survival. Founded in 2000 by Irit Arbel, PhD, the company is currently led by President and CEO Chaim Lebovits, who has directed the firm’s strategic vision since 2015. The leadership team features high-pedigree executives including EVP and Chief Operating Officer Haro Hartounian, PhD, an expert in biopharmaceutical manufacturing, and EVP and Chief Medical Officer Bob Dagher, MD, who previously held senior roles at GSK and Sanofi. Uri Yablonka serves as EVP and Chief Business Officer, managing corporate development and the company's academic roots in Tel Aviv University technology. The board of directors includes former Co-CEO Stacy Lindborg, PhD, and the company maintains institutional backing from notable investors such as Armistice Capital and BlackRock.